Drometa 4 mg Injection is administered intravenously (IV) or intramuscularly (IM), as directed by a healthcare professional. IV doses should be given slowly.

Ondansetron selectively blocks 5-hydroxytryptamine3 (5-HT3) receptors, which are located both centrally in the chemoreceptor trigger zone (CTZ) and peripherally on vagal nerve terminals in the gastrointestinal tract. This action inhibits the initiation of the vomiting reflex.

• •Hypersensitivity to ondansetron or any component of the formulation.
• •Concomitant use with apomorphine.

Store below 30°C. Protect from light. Do not freeze.

Symptoms of overdose include transient visual disturbances, severe constipation, hypotension, and vasovagal episodes with transient AV block and QT prolongation. Treatment should be symptomatic and supportive, with ECG monitoring.

Pregnancy Category B. Use only if clearly needed. Ondansetron is excreted in the milk of lactating animals; it is unknown whether it is excreted in human milk. Caution should be exercised when administered to a nursing woman.